TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells. / Zhu, Chunhua; Di, Dongmei; Zhang, Xiaoying; Luo, Guanghua; Wang, Zongchun; Wei, Jiang; Shi, Yuanping; Berggren Söderlund, Maria; Nilsson-Ehle, Peter; Xu, Ning.

I: Lipids in Health and Disease, Vol. 10, 2011.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Zhu, Chunhua ; Di, Dongmei ; Zhang, Xiaoying ; Luo, Guanghua ; Wang, Zongchun ; Wei, Jiang ; Shi, Yuanping ; Berggren Söderlund, Maria ; Nilsson-Ehle, Peter ; Xu, Ning. / TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells. I: Lipids in Health and Disease. 2011 ; Vol. 10.

RIS

TY - JOUR

T1 - TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells

AU - Zhu, Chunhua

AU - Di, Dongmei

AU - Zhang, Xiaoying

AU - Luo, Guanghua

AU - Wang, Zongchun

AU - Wei, Jiang

AU - Shi, Yuanping

AU - Berggren Söderlund, Maria

AU - Nilsson-Ehle, Peter

AU - Xu, Ning

PY - 2011

Y1 - 2011

N2 - Background: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. Materials and methods: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. Results: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. Conclusion: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.

AB - Background: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317. Materials and methods: Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR. Results: When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1. Conclusion: The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.

KW - Liver X Receptor

KW - Farnesoid X Receptor

KW - Caco-2 cell line

KW - Apolipoprotein M

U2 - 10.1186/1476-511X-10-199

DO - 10.1186/1476-511X-10-199

M3 - Article

C2 - 22054074

VL - 10

JO - Lipids in Health and Disease

JF - Lipids in Health and Disease

SN - 1476-511X

ER -